US 12,410,240 B2
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
Wei Bu, Potomac, MD (US); Masaru Kanekiyo, North Bethesda, MD (US); Michael Gordon Joyce, Washington, DC (US); and Jeffrey I. Cohen, Silver Spring, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US)
Filed by The U.S.A., as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US)
Filed on Feb. 13, 2024, as Appl. No. 18/440,344.
Application 17/553,139 is a division of application No. 16/608,386, granted, now 11,236,151, issued on Feb. 1, 2022, previously published as PCT/US2018/029463, filed on Apr. 25, 2018.
Application 18/440,344 is a continuation of application No. 17/553,139, filed on Dec. 16, 2021, granted, now 11,926,656.
Claims priority of provisional application 62/490,023, filed on Apr. 25, 2017.
Prior Publication US 2024/0174735 A1, May 30, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/08 (2006.01); A61K 38/00 (2006.01); C07K 14/05 (2006.01)
CPC C07K 16/085 (2013.01) [C07K 14/05 (2013.01); A61K 38/00 (2013.01); C07K 2317/10 (2013.01); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01)] 16 Claims
 
1. An isolated antibody that binds Epstein Barr Virus (EBV) gp350 protein, comprising a variable heavy (VH) domain and a variable light (VL) domain, wherein:
(a) the VH domain comprises the complementarity determining region 1 (CDR1), CDR2 and CDR3 sequences of SEQ ID NO: 1, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 6;
(b) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 11, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
(c) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 21, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 26;
(d) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 31, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 36;
(e) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 41, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 46;
(f) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 161, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 166, wherein the antibody is an engineered antibody;
(g) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 171, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 176, wherein the antibody is an engineered antibody;
(h) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 181, the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 186, wherein the antibody is an engineered antibody;
(i) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 191, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 196, wherein the antibody is an engineered antibody;
(j) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 201, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 206, wherein the antibody is an engineered antibody;
(k) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 211, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 216, wherein the antibody is an engineered antibody;
(l) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 221, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 226, wherein the antibody is an engineered antibody;
(m) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 231, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 236, wherein the antibody is an engineered antibody;
(n) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 241, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 246, wherein the antibody is an engineered antibody;
(o) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 251, and the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 256, wherein the antibody is an engineered antibody;
(p) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 261, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 266, wherein the antibody is an engineered antibody;
(q) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 271, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 276, wherein the antibody is an engineered antibody; or
(r) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 281, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 286, wherein the antibody is an engineered antibody.